Abstract Number: PB0311
Meeting: ISTH 2021 Congress
Theme: Diagnostics and OMICs » Biomarkers of Thrombosis and Hemostasis
Background: Chronic myeloproliferative neoplasms (MPN) are stem cell disorders characterized by myeloid proliferation and increased blood cell counts. Large-vessel thrombosis and microvascular disturbances remains the main complication of MPN patients. The mechanisms leading to it are complex and include endothelial dysfunction.
Aims: The aim of our study was to assess potential endothelial impairment in patients with MPN by measuring such biomarkers as ristocetin-cofactor von Willebrand’s factor activity (vWF:RCo), antigen (vWF:Ag), and homocysteine (HCY).
Methods: We studied vWF:RCo activity (%), vWF:Ag (%) and HCY levels (μmol/l) in 173 MPN patients and 68 healthy volunteers. Statistical analysis was performed by non-parametric methods (median (Me), 95% confidence interval (95% CI), Mann-Whitney U test and Spearman’s rank correlation coefficient (Rs), Statistica 12.0), p<0.05 was considered statistically significant.
Results: The vWF:RCo activity and vWF:Ag were significantly higher in patients compared with controls, and no difference in the HCY levels was observed (data shown in the table).
| Parameter (Me, 95% CI) | Patients with MPN N=173 |
Controls N=68 |
| vWF:RCo , % | 105,0* (50,0 – 270,3) | 97,0 (63,0 – 144,3) |
| vWF: Ag, % | 130,0* (71,1 – 381,7) | 107,0 (74,6 – 161,7) |
| HCY, μmol/l | 9,2 (5,6 – 23,7) | 10,1 (5,1 – 14,8) |
Table 1* – p=0,001 with controls.
Also, there was no relationship between these parameters and previous thrombotic complications history. In the same time, we found weak but significant correlation between HCY levels and both vWF:RCo (Rs=0,21) and vWF:Ag (Rs=0,25), p=0,03.
Conclusions: The increase of vWF:RCo activity and vWF:Ag may reflect a chronic endothelial impairment and predispose to thromboembolic complications, although much molecular details still need to be clarified.
To cite this abstract in AMA style:
Smirnova O, Silina N, Korsakova N, Golovina O, Efremova E, Fominykh M, Voloshin S, Papayan L. Circulating Biologic Markers of Endothelial Dysfunction in Chronic Myeloproliferative Neoplasms [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/circulating-biologic-markers-of-endothelial-dysfunction-in-chronic-myeloproliferative-neoplasms/. Accessed May 16, 2022.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/circulating-biologic-markers-of-endothelial-dysfunction-in-chronic-myeloproliferative-neoplasms/